EW
EIDX

Evoke Wealth’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Evoke Wealth’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-57
Closed -$2.79K – 1243
2020
Q1 		$2.79K Buy
+57
New +$2.9K ﹤0.01% 745

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Evoke Wealth's EIDX Position: Q2 2020 in Review

Evoke Wealth sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q2 2020, closing a stake of 57 shares — an estimated $2.79K sold.

Evoke Wealth first reported a position in EIDX in Q1 2020 and held it in 1 quarter. The position peaked at $2.79K in Q1 2020. 92 funds tracked by Wall St. Rank hold EIDX as of Q2 2020.

  • Evoke Wealth reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Evoke Wealth sold 57 Eidos Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $2.79K.
  • Evoke Wealth first reported a position in Eidos Therapeutics, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • Evoke Wealth's Eidos Therapeutics, Inc. Common Stock position peaked at $2.79K in Q1 2020.
  • 92 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Evoke Wealth's 13F filing for Q2 2020, filed 10 Aug 2020.